CUNY SPH receives $5.2 million NIH grant renewal for cancer genomics research
NEW YORK, June 25, 2024 /PRNewswire/ -- The Informatics Technology for Cancer Research (ITCR) program of the NIH National Cancer...
Cancer
Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria
INDIANAPOLIS, June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow...
Function Emerges as the Fastest-Growing Health Platform in the US with Unique Approach that Starts with 100+ Lab Tests
The company's latest $53M raise will help further its mission of empowering everyone to live 100 healthy years AUSTIN, Texas,...
Erie County Medical Center Leverages Brook Health’s AI and Remote Care Platform to Transform Hypertension Management
Collaboration Doubles Blood Pressure Control for High-Risk Patients in 12 Weeks BUFFALO, N.Y., June 25, 2024 /PRNewswire/ -- Brook Health,...
Carrum Health Expands Cancer Care Solution to Over 400 Facilities Nationwide, Extending Value-Based Treatment for Nearly All Cancer Types
Carrum now has the largest Centers of Excellence network for cancer care in the country offering high quality local access...
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
The pooled analysis included data from 4 international clinical trials spanning an array of hard-to-treat indications including skin, head &...
Industry Leader John Maraganore, Ph.D., Joins Cybrexa Therapeutics as Strategic Advisor
NEW HAVEN, Conn., June 25, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class...
Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances
WARREN, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage...
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing...
Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024
Tonix’s live virus vaccine TNX-801 is designed to provide long-term protection from mpox and smallpox with one dose TNX-801 vaccination...
New Study From Inovalon and Genentech Finds Racial Disparities In Emergency Department Visits For Liver Cancer Care
Research Reveals How Social Drivers of Health Influence Higher Rates of Emergency Department Utilization for Black and Hispanic Hepatocellular Carcinoma...
GeneType Identifies 79.5% of People Tested are at Risk of Serious Disease
Results from commercial sales of predictive testing across the US and Australia establish clear advantages of geneType Risk Assessment Tests...
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
Media Release SYDNEY, AUSTRALIA, June 25, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),...
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ:...
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC
SHANGHAI, June 25, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading...
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved...
Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension
Gerardo Ubaghs brings high-profile global biopharma strategic and capital markets experience as newly appointed Chief Financial Officer (CFO)Company adds $20...
Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
WÜRZBURG, Germany, June 25, 2024 (GLOBE NEWSWIRE) -- Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler...
Engitix appoints two additional international biotech industry leaders as Scientific Advisors
LONDON, June 25, 2024 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes...
17 winners receive the 2024 MAP Award for high performance in revenue cycle
LAS VEGAS, June 24, 2024 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association (HFMA) announced the 2024 winners of the...